Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › avacopan

avacopan

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of avacopan

4 trials tracked of avacopan: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 1007 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1
  1. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 1,007 cited
  2. Phase 2 Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Completed
  3. Phase 2 Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) Completed
  4. Phase 1 A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Avacopan Demonstrates Non-Inferiority to Prednisone Taper in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Rheumatology RCT
Avacopan Demonstrates Non-Inferiority to Prednisone Taper in Granulomatosis with Polyangiitis and Microscopic Polyangiitis Trial shows avacopan works as well as prednisone for vasculitis
A Phase 3 trial shows avacopan maintains efficacy comparable to prednisone while significantly reducing glucocorticoid exposure for GPA and …
A new trial shows that patients with specific autoimmune conditions can achieve remission using avacopan instead of tapering off steroid med…
medRxiv Aug 14, 2026
Avacopan is associated with high remission rates and low relapse in ANCA-associated vasculitis
Rheumatology Sys. Review
Avacopan is associated with high remission rates and low relapse in ANCA-associated vasculitis Avacopan shows high remission rates for ANCA-associated vasculitis
This systematic review and meta-analysis of 71 studies indicates that avacopan is associated with an 87% remission rate at 6 months and a 93…
New data shows avacopan helps many patients with ANCA-associated vasculitis reach remission while reducing the need for steroid use.
medRxiv Jun 18, 2026